# Ozempic-Style Drugs May Slow Biological Aging, Not Just Shrink Waistlines

*GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension.*

- **Evidence Level**: Moderate
- **Facts**: Design: Journal Article
- **Publication Types**: Journal Article, Review
- **Journal**: Experimental gerontology
- **Sample Size**: N/A
- **Authors**: Al-Ali D, El Hajj N
- **Graded and published**: 2026-09-14
- **Last edited**: 2026-09-16
- **Topics**: GLP-1, epigenetic aging, longevity drugs
- **DOI**: https://doi.org/10.1016/j.exger.2026.113325
- **Original Source**: https://pubmed.ncbi.nlm.nih.gov/42735804/

## Summary

GLP-1 drugs like semaglutide cut deaths and heart problems by more than their weight and blood sugar effects alone would explain. This review pulls together the evidence, including a 2025 trial where 32 weeks of semaglutide slowed three well-known epigenetic clocks (blood tests that estimate how fast you're aging). Researchers think pathways like AMPK and SIRT1, plus gut bacteria changes, may be involved. It's still early, and no trial has been designed specifically to test aging as the main outcome.

## Practical Takeaway

This review suggests GLP-1 drugs may affect aging biology beyond weight loss, but confirmation trials are pending.

---

_Canonical: https://longevity-germany.com/en/research/ozempic-style-drugs-may-slow-biological-aging-not-just-shrink-waistlines · Part of Longevity Cities · Updated 2026-09-16_